NAS:IART Key Ratios
| Market Cap $ M | 1,302.30 |
| Enterprise Value $ M | 3,077.10 |
| P/E(ttm) | -- |
| PE Ratio without NRI | 6.78 |
| Forward PE Ratio | 6.81 |
| Price/Book | 1.25 |
| Price/Sales | 0.78 |
| Price/Free Cash Flow | 113.14 |
| Price/Owner Earnings | 78.25 |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 1,647.00 |
| EPS (TTM) $ | -0.09 |
| Beneish M-Score | -2.69 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | 33.56 |
| EV-to-EBITDA | 12.55 |
| PEG | -- |
| Shares Outstanding M | 77.77 |
| Net Margin (%) | -0.44 |
| Operating Margin % | 3.98 |
| Pre-tax Margin (%) | -0.01 |
| Quick Ratio | 2.11 |
| Current Ratio | 3.60 |
| ROA % (ttm) | -0.20 |
| ROE % (ttm) | -0.70 |
| ROIC % (ttm) | 2.09 |
| Dividend Yield % | -- |
| Altman Z-Score | 1.31 |
IART Number of Guru Trades
IART Volume of Guru Trades
Gurus Latest Trades with NAS:IART
NAS:IART is held by these investors
Integra Lifesciences Holdings Corp Insider Transactions
Guru Commentaries on NAS:IART
Integra LifeSciences was mentioned as one of the fund’s health care holdings that were among the largest detractors in performance during April. However, there was no specific argument made regarding its future performance or valuation.
Integra LifeSciences was mentioned as one of the fund’s health care holdings that were among the largest detractors in performance during April. However, there was no specific argument made regarding its future performance or valuation.
Integra LifeSciences was mentioned as one of the fund's health care holdings that were among the largest detractors in performance during April. However, there was no specific argument made regarding its future potential or valuation.
News about NAS:IART
Total 0- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
